Bright Minds Biosciences Inc. is a US-listed company in the biotechnology industry. Its financial year ends in September.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
Not valued: the figures our models need are missing or failed our data-quality checks.
Price vs value
No model value: limited reported history: available models are shown without a Buy/Hold/Sell rating. How we value companies.
Bright Minds Biosciences Inc. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders0 buying, 1 selling0 purchases and 1 sale by directors and officers, last 12 monthsInsider trades
- Funds66 adding, 29 cuttingOf 28 active managers that changed their stake, 19 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 85% in the quarter to 2026-06-30, the 4th beat in the last four quarters.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
- Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.
Things to watch
- Share dilution. Diluted shares rose 59.6% in a year.
- Heavily shorted. 10.9% of the shares available to trade are sold short (5.8 days of average volume to cover).
Latest results
- Earnings per share
- -$0.24 against an average estimate of -$1.64: beat by 85.3%
- Next report
- December 22, 2026
Price chart
- 1 day-52.3%
- 1 week-48.7%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-1.27
Growth
- Share count change
- +59.6%
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for DRUG from the sources we follow. See filings →
Valuation models
We value Bright Minds Biosciences Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no positive revenue in the latest twelve months |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Bright Minds Biosciences Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: December 22, 2026, after the close.
Analysts' consensus
No analyst estimates are published for Bright Minds Biosciences Inc.: too few analysts cover it.
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$1.64 | −$0.24 | +85.3% |
| Mar 2026 | −$1.26 | −$1.09 | +13.5% |
| Dec 2025 | −$1.19 | −$0.97 | +18.1% |
| Sept 2025 | −$1.00 | −$0.58 | +41.8% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 10.9% of tradable shares
- Days to cover
- 5.84 at average volume
- Short interest, 1 month
- −11% to October 15, 2026
- Held by institutions
- 95% of shares
- Held by insiders
- 11.5% of shares
- Employees
- 26 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Financial health
- Short-term assets cover short-term liabilities $61m of assets due within a year against $2m of liabilities due within a year.
- Short-term assets cover long-term liabilities $61m short-term assets against $29,618 of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Dividends, buybacks and capital spending
- Diluted share count
- +59.6%
- year over year
Who owns it
Funds buying and selling- Reported value
- $654M
- Institutions reporting
- 100
- Shares held vs prior quarter
- ▲ 1.3%
- Positions opened / closed
- 19 / 12
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Jupiter Topco LLC | $94.8M | 1.3M | 14.5% | — |
| Cormorant Asset Management, LP | $63.2M | 900K | 9.7% | ▼ 15.0% |
| Blackrock, Inc. | $48.2M | 686K | 7.4% | ▲ 10.3% |
| Vivo Capital, LLC | $39.1M | 557K | 6.0% | 0.0% |
| Vestal Point Capital, LP | $38.3M | 545K | 5.9% | ▲ 10.7% |
| Braidwell LP | $34M | 484K | 5.2% | ▼ 10.4% |
| Driehaus Capital Management LLC | $30.4M | 433K | 4.7% | ▲ 0.2% |
| Balyasny Asset Management L.P. | $24.2M | 345K | 3.7% | ▲ 16.1% |
| Adage Capital Partners Gp, L.L.C. | $23.5M | 335K | 3.6% | ▼ 32.4% |
| Point72 Asset Management, L.P. | $23M | 327K | 3.5% | New |
| Deerfield Management Company, L.P. | $19.9M | 283K | 3.0% | 0.0% |
| RA Capital Management, L.P. | $18.6M | 265K | 2.8% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Bright Minds Biosciences Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Cormorant Asset Management, Lp 10% owner | April 28, 2026 | Sell | 109,331 | $89.50 | $9.8M |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Bright Minds Biosciences Inc. in brief
- What does Bright Minds Biosciences Inc. do?
- Bright Minds Biosciences Inc. is a US-listed company in the biotechnology industry. Its financial year ends in September.
- What is Bright Minds Biosciences Inc.'s stock ticker?
- Bright Minds Biosciences Inc. trades under the ticker DRUG on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Bright Minds Biosciences Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Jupiter Topco LLC, Cormorant Asset Management, LP and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Bright Minds Biosciences Inc. stock?
- Over the last 12 months, Bright Minds Biosciences Inc.'s directors and officers reported 0 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
- When is Bright Minds Biosciences Inc.'s next earnings date?
- Around December 22, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Bright Minds Biosciences Inc. announces its own schedule.
Follow research on Bright Minds Biosciences Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.